Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
After Ditching Promising Drug, Everest Medicines Bets on mRNA
The drug maker surprised investors last year when it halted its tie-up with Gilead to develop the breast cancer drug Trodelvy. Now it says it will focus on mRNA vaccinesKey…
Surging Beigene Catches Case of Forex Flu
The drug maker’s net loss grew in the third quarter due to weakness in the Chinese yuan, even as its revenue nearly doubledKey Takeaways:Surging sales for its two self-developed drugs…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
Booster Shot for Brii Biosciences with First Covid Drug Launch
Brii Biosciences announced the commercial launch of its injectable Covid antibody treatment, which will be covered by government medical insurance in many parts of the country Key Takeaways: The antibody…
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
U.S. securities regulator singles out company for potential delisting, a week after Hutchmed announced its CEO will step down after almost 22 years Key Takeaways U.S. securities regulator says Hutchmed…
Lacking Revenue, Lepu Biopharma Chases IPO to Revive War Chest
The cutting-edge cancer treatment company has not generated any revenue from its products, and only has enough money to last another three months Key takeaways: Lepu Biopharma has yet to…
Recent Articles
RELATED ARTICLES
-
Junshi narrows its losses but delivers no cure for share price woes
1877.HK 688180.SHG -
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
